EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Leveraging cDC1 biology and function for enhanced immunotherapy

Ross W Ward iD, Uddipan Kar iD, Sreekumar Balan iD, Nina Bhardwaj iD

Journal of Experimental Medicine · 06.07.2026 · 223 (7)

DOI: 10.1084/jem.20241199 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Experimental Medicine, online erschienen am 10.06.2026. Verfasst von Ross W Ward und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 170 Literaturangaben. Gefördert von: Icahn School of Medicine at Mount Sinai, American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional type 1 dendritic cells (cDC1s) promote antitumor immunity through efficient cross-presentation of tumor antigens and production of key mediators. Crucially, in the tumor microenvironment, cDC1s orchestrate immune hubs and signaling axes that support T cell responses and are associated with improved patient outcomes. During tumor progression, however, cDC1 activity is increasingly constrained by immunosuppressive signals and inhibitory cellular interactions. Many immunotherapies, including immune checkpoint blockade and adoptive cell transfer, depend on functional cDC1 populations for optimal efficacy, underscoring the need to define both the mechanisms that enable cDC1-mediated immunity and those that suppress it. Emerging strategies aim to harness cDC1s by expanding their numbers, reprogramming suppressed DC states, or strengthening interactions with CD8+ and CD4+ T cells and natural killer cells. Here, we discuss the molecular pathways, cellular phenotypes, and spatial features that govern cDC1 function, highlight the prognostic and predictive value of cDC1-associated signatures, and evaluate therapeutic approaches that leverage cDC1 biology to improve cancer treatment and durability of response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsImmunotherapyNeoplasmsHumansAnimalsTumor MicroenvironmentKiller Cells, Natural

Autor:innen und Institutionen

  • Division of Hematology & Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA.

ORCID-Profile: Ross W Ward, Uddipan Kar, Sreekumar Balan, Nina Bhardwaj

Förderung

  • Icahn School of Medicine at Mount Sinai
  • American Cancer Society

Zitieren

APA

Ward, R. W., Kar, U., Balan, S., & Bhardwaj, N. (2026). Leveraging cDC1 biology and function for enhanced immunotherapy. Journal of Experimental Medicine, 223(7). https://doi.org/10.1084/jem.20241199

Vancouver

Ward RW, Kar U, Balan S, Bhardwaj N. Leveraging cDC1 biology and function for enhanced immunotherapy. Journal of Experimental Medicine. 2026;223(7). doi:10.1084/jem.20241199

BibTeX
@article{Ward2026,
  author = {Ward, Ross W and Kar, Uddipan and Balan, Sreekumar and Bhardwaj, Nina},
  title = {Leveraging cDC1 biology and function for enhanced immunotherapy},
  journal = {Journal of Experimental Medicine},
  year = {2026},
  volume = {223},
  number = {7},
  doi = {10.1084/jem.20241199}
}
Kostenlos starten →